Molecular Simulation of Coffee Beans’ Natural Products as Lead Compounds for Stroke Remedy

Abstract:

The consumption of coffee has its health benefits and its risks, one of the risks is mostly related to cardiovascular diseases. One of the diseases is hypertension which is considered “the silent killer” as it is a serious condition which promotes other complications and typically has no symptoms for a period of time until it has done significant damage. Acute hypertension can lead to a stroke. It is a very serious medical condition where the blood flow to the brain is poor, causing the death of cells within the brain. Some medications, surgeries and other healthcare programs are capable of controlling stroke, but stroke still remains to be the main cause of death and disability in Indonesia. However, provided that the consumption is restrained, multiple studies show that coffee consumption actually can reduce the risk of getting a stroke, by consuming between 2 to 4 cups of coffee per day. Additionally, coffee can reduce the likelihood of blood clots from forming and is likely to alter the blood vessel physiology. Therefore, the current project will explore the possibility of utilization of bioactive compounds other than caffeine from coffee beans that can be implemented in a form of supplements to help in treating patients both with stroke symptoms and during the recovery phase. Protein docking analysis is an alternative way to search and predict for drug discovery. Through protein docking analysis we can gain information on the bioactive compounds and their respective interactions with the target. Based on the virtual screening pipeline, it is predicted that Dehydrokahweol could elicit possible lead for the anti-stroke activity.

• Periodical: Engineering Headway (Volume 6)
• Pages: 145-155
• DOI: https://doi.org/10.4028/p-K5DElO
• Online since: April 2024
• Authors: Muhammad Rubani, Arli Aditya Parikesit*
• Keywords: Bioactive Compound, Biological Pathway, Coffee Protein, Protein Docking Analysis

References

[1] FAO publications catalogue 2022. FAO, 2022.

DOI: 10.4060/cc2323en

[2] J. Gallardo-Ignacio, P. Nicasio-Torres, A. Santibáñez, S. L. Cabrera-Hilerio, and F. Cruz-Sosa, "Ethnopharmacological study of the genus Coffea and compounds of biological importance," Rev Mex Ing Quim, vol. 21, no. 3, pp. Bio2856–Bio2856, Oct. 2022.

DOI: 10.24275/RMIQ/BIO2856

[3] M. Jeszka-Skowron, A. Zgoła-Grześkowiak, and T. Grześkowiak, "Analytical methods applied for the characterization and the determination of bioactive compounds in coffee," European Food Research and Technology, vol. 240, no. 1, p.19–31, Jan. 2015.

DOI: 10.1007/s00217-014-2356-z

[4] K. Socała, A. Szopa, A. Serefko, E. Poleszak, and P. Wlaź, "Neuroprotective Effects of Coffee Bioactive Compounds: A Review," International Journal of Molecular Sciences 2021, Vol. 22, Page 107, vol. 22, no. 1, p.107, Dec. 2020.

DOI: 10.3390/IJMS22010107

[5] P. Priyono and R. A. Putranto, "Molecular markers and their application for DNA fingerprinting and genetic diversity studies in Coffea species," Menara Perkeb, vol. 82, no. 1, p.39–50, 2014.

DOI: 10.22302/ppbbi.jur.mp.v82i1.30

[6] T. N. Rochmah, I. T. Rahmawati, M. Dahlui, W. Budiarto, and N. Bilqis, "Economic burden of stroke disease: A systematic review," Int J Environ Res Public Health, vol. 18, no. 14, p.7552, Jul. 2021.

DOI: 10.3390/ijerph18147552

[7] WHO, "The top 10 causes of death," Fact Sheets, 2020. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed Feb. 03, 2023).

[8] E. J. Benjamin et al., "Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association," Circulation, vol. 139, no. 10, pp. e56–e528, Mar. 2022.

DOI: 10.1161/CIR.0000000000000659

[9] J. D. Spence et al., "Vitamin Intervention for Stroke Prevention (VISP) Trial: Rationale and Design," Neuroepidemiology, vol. 20, no. 1, p.16–25, 2001.

DOI: 10.1159/000054753

[10] P. Yi, Z. Zhang, S. Huang, J. Huang, W. Peng, and J. Yang, "Integrated meta-analysis, network pharmacology, and molecular docking to investigate the efficacy and potential pharmacological mechanism of Kai-Xin-San on Alzheimer's disease," Pharm Biol, vol. 58, no. 1, p.932–943, Jan. 2020.

DOI: 10.1080/13880209.2020.1817103

[11] A. A. Parikesit, "Introductory Chapter: The Contribution of Bioinformatics as Blueprint Lead for Drug Design," in Molecular Insight of Drug Design, Ivana Glavic, Ed. London: InTech, 2018, p.7.

DOI: 10.5772/intechopen.79664

[12] A. Aditya Parikesit and R. Nurdiansyah, "Introductory Chapter: Current Perspective of COVID-19 Drugs," COVID-19 Drug Development - Recent Advances, New Perspectives and Applications, Dec. 2022.

DOI: 10.5772/INTECHOPEN.105537

[13] Y. Aurora et al., "Identification of Flavonoids of Kalanchoe Pinnata as Candidate Drugs for COVID-19 Gamma-Variant Treatment," Malaysian Journal of Fundamental and Applied Sciences, vol. 18, no. 6, p.630–643, Dec. 2022.

DOI: 10.11113/MJFAS.V18N6.2594

[14] A. Wicaksono et al., "Screening Rafflesia and Sapria Metabolites Using a Bioinformatics Approach to Assess Their Potential as Drugs," Philipp J Sci, vol. 151, no. 5, p.1771–1791, 2022, Accessed: Jul. 21, 2022. [Online]. Available: https://philjournalsci.dost.gov.ph/accepted-articles/115-vol-151-no-5-october-2022/1694-screening-rafflesia-and-sapria-metabolites-using-a-bioinformatics-approach-to-assess-their-potential-as-drugs

DOI: 10.56899/151.05.20

[15] R. F. Wisnumurti, S. Aslanzadeh, and A. A. Parikesit, "Computational Examination Of Flavonoid Compounds: Utilization Of Molecular Simulation To Discover Drug Candidates For COVID-19," Rasayan Journal of Chemistry, vol. 15, no. 2, p.1132–1136, 2022.

DOI: 10.31788/RJC.2022.1526877

[16] M. A. F. Nasution, A. A. Parikesit, and U. S. F. Tambunan, "Discovery of novel drug candidates based on herbaric acid derivates as potential inhibitors of the hedgehog signaling pathway in cervical cancer therapeutics," J Phys Conf Ser, vol. 1442, p.012052, Jan. 2020.

DOI: 10.1088/1742-6596/1442/1/012052

[17] P. W. Rose et al., "The RCSB Protein Data Bank: New resources for research and education," Nucleic Acids Res, vol. 41, 2013.

DOI: 10.1093/nar/gks1200

[18] D. Weininger, "SMILES. 3. DEPICT. Graphical depiction of chemical structures," J Chem Inf Model, vol. 30, no. 3, p.237–243, Aug. 1990.

DOI: 10.1021/ci00067a005

[19] A. Lagunin, A. Stepanchikova, D. Filimonov, and V. Poroikov, "PASS: prediction of activity spectra for biologically active substances," Bioinformatics, vol. 16, no. 8, p.747–748, Aug. 2000.

DOI: 10.1093/bioinformatics/16.8.747

[20] W. P. Walters, "Going further than Lipinski's rule in drug design," Expert Opinion on Drug Discovery, vol. 7, no. 2. Taylor & Francis, p.99–107, Feb. 2012.

DOI: 10.1517/17460441.2012.648612

[21] T. Makarewicz and R. Kaźmierkiewicz, "Molecular dynamics simulation by GROMACS using GUI plugin for PyMOL.," J Chem Inf Model, vol. 53, no. 5, p.1229–34, May 2013.

DOI: 10.1021/ci400071x

[22] D. Schneidman-Duhovny, Y. Inbar, R. Nussinov, and H. J. Wolfson, "PatchDock and SymmDock: Servers for rigid and symmetric docking," Nucleic Acids Res, vol. 33, no. SUPPL. 2, pp. W363-7, Jul. 2005.

DOI: 10.1093/nar/gki481

[23] S. Salentin, S. Schreiber, V. J. Haupt, M. F. Adasme, and M. Schroeder, "PLIP: Fully automated protein-ligand interaction profiler," Nucleic Acids Res, vol. 43, no. W1, pp. W443–W447, Jul. 2015.

DOI: 10.1093/nar/gkv315

[24] A. Kuriata et al., "CABS-flex 2.0: A web server for fast simulations of flexibility of protein structures," Nucleic Acids Res, vol. 46, no. W1, pp. W338–W343, Jul. 2018.

DOI: 10.1093/nar/gky356

[25] M. Blaszczyk, M. Jamroz, S. Kmiecik, and A. Kolinski, "CABS-fold: Server for the de novo and consensus-based prediction of protein structure.," Nucleic Acids Res, vol. 41, no. Web Server issue, pp. W406-11, Jul. 2013.

DOI: 10.1093/nar/gkt462

[26] M. A. Rubani and A. A. Parikesit, "In Silico Screening of Coffee Plant Natural Products as Lead Compounds for Stroke Remedy (Supplementary material)," Feb. 2023.

[27] O. Iborra-Egea, F. Rueda, C. García-García, E. Borràs, E. Sabidó, and A. Bayes-Genis, "Molecular signature of cardiogenic shock," Eur Heart J, vol. 41, no. 39, p.3839–3848, Oct. 2020.

DOI: 10.1093/EURHEARTJ/EHZ783

[28] A. Vega et al., "The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients," Clin Kidney J, vol. 13, no. 2, p.172–178, Apr. 2020.

DOI: 10.1093/CKJ/SFZ056

[29] S. Liabeuf et al., "Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients," Kidney Int, vol. 82, no. 12, p.1297–1303, Dec. 2012.

DOI: 10.1038/KI.2012.301

[30] B. A. Cunha, C. M. Sibley, and A. M. Ristuccia, "Doxycycline," Ther Drug Monit, vol. 4, no. 2, p.115–135, 1982.

DOI: 10.1097/00007691-198206000-00001